Edition:
United States

Astellas Pharma Inc (ALPMF.PK)

ALPMF.PK on OTC Markets Group

13.47USD
19 Jan 2017
Change (% chg)

$-0.64 (-4.54%)
Prev Close
$14.11
Open
$13.50
Day's High
$13.50
Day's Low
$13.47
Volume
200
Avg. Vol
3,347
52-wk High
$18.50
52-wk Low
$12.84

Select another date:

Tue, Jan 10 2017

BRIEF-Astellas terminates agreement with UMN Pharma for cell culture based influenza vaccine programs

* Says co terminates agreement with UMN Pharma Inc , for the co-development and Astellas' exclusive commercialization of ASP7374 and ASP7373, the cell culture based influenza vaccine programs in Japan

BRIEF-Astellas to acquire Ganymed Pharmaceuticals 422 mln euros

* Atellas will pay eur 422 million to acquire 100% of equity in Gnymed

BRIEF-Astellas to buy Ganymed Pharmaceuticals for 422 mln euros

* Astellas says to buy Ganymed Pharmaceuticals for EUR 422 million ($460 million)

BRIEF-Astellas Pharma Inc's operating profit likely rose roughly 20% on the year for April-September half - Nikkei

* Astellas Pharma Inc's operating profit likely rose roughly 20% on the year to 160 billion yen ($1.54 billion) or so for April-September half - Nikkei

Fitch Assigns First-Time 'BBB-' Rating to Beijing Capital Development

(The following statement was released by the rating agency) HONG KONG, October 20 (Fitch) Fitch Ratings has assigned Beijing Capital Development Holding (Group) Co., Ltd. (known by its abbreviated Chinese name Shokai Group) a Long-Term Foreign-Currency Issuer Default Rating (IDR) of 'BBB-' with Stable Outlook. Fitch has also assigned the homebuilder a foreign-currency senior unsecured rating of 'BBB-'. Fitch has also assigned Bright Galaxy International Limited's (Bright Galaxy) proposed US

BRIEF-Astellas Pharma files lawsuit against patent infringement of Myrbetriq in U.S.

* Says the co and its subsidiaries jointly filed a lawsuit with the United States District Court against Actavis Elizabeth LLC and its affiliates, who filed an abbreviated new drug application for a generic version of Astellas' mirabegron (generic name) product sold under the trademark Myrbetriq in the U.S.

BRIEF-Cytokinetics announces early termination of Hart-Scott-Rodino waiting period

* Announces Early Termination Of Hart-Scott-Rodino waiting period for expanded collaboration with astellas

BRIEF-Astellas Pharma gets approval for medicine for hyperphosphatemia in Japan

* Says the co received a marketing approval of Kiklin Granules 86.2% for the indication of treatment of hyperphosphatemia in patients with chronic kidney disease in Japan

Astellas, Vical herpes vaccine fails mid-stage study

Japan's Astellas Pharma Inc and San Diego-based Vical Inc said their experimental herpes vaccine failed a mid-stage study involving certain kidney transplant patients.

BRIEF-Vical and Astellas study on CMV vaccine fails to meet its primary endpoint

* Results from study demonstrated that trial did not meet its primary endpoint

Select another date: